DexCom (DXCM) Tops Q2 EPS by 5c, Names CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
DexCom (DXCM) PT Lowered to $90 at BMO Capital Following 2Q on 'Near-Term Medicare Reimbursement Disruption'
August 2, 2017 9:49 AM EDTBMO Capital lowered its price target on DexCom (NASDAQ: DXCM) to $90.00 (from $105.00) while maintaining a Outperform rating, following the company's second quarter earnings announcement.
Analyst Joanne Wuensch notes the company delivered second quarter earnings per share and revenue results above consensus projections, while... More
DexCom (DXCM) PT Lowered to $92 at Oppenheimer Following 2Q
August 2, 2017 9:36 AM EDTOppenheimer lowered its price target on DexCom (NASDAQ: DXCM) to $92.00 (from $98.00) while maintaining a Outperform rating. 2Q17 revenue of $170.6M was ahead of the consensus estimate of $166.6M. The beat was both in the US and international. US sales were ~$140.8M, above... More
